Cardiff Oncology, Inc.
CRDF
$1.53
$0.032.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -83.13% | 102.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.13% | 102.50% | |||
| Cost of Revenue | 33.30% | -38.09% | |||
| Gross Profit | -39.16% | 40.18% | |||
| SG&A Expenses | 104.54% | -23.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 59.74% | -33.27% | |||
| Operating Income | -64.18% | 34.63% | |||
| Income Before Tax | -71.08% | 35.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -71.08% | 35.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -71.08% | 35.90% | |||
| EBIT | -64.18% | 34.63% | |||
| EBITDA | -64.92% | 34.88% | |||
| EPS Basic | -68.72% | 36.40% | |||
| Normalized Basic EPS | -68.76% | 36.41% | |||
| EPS Diluted | -68.72% | 36.40% | |||
| Normalized Diluted EPS | -68.76% | 36.41% | |||
| Average Basic Shares Outstanding | 1.36% | 0.83% | |||
| Average Diluted Shares Outstanding | 1.36% | 0.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||